Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

FDA approves hepatitis B shot that may let some patients stop all treatment (opens in a new tab)

medicalxpress.com · 2026-10-23

Short answerEvidenceSource

Short answer

Mostly not supported

Mostly not supported.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 2 supported
  • 6 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mostly not supported

Every claim we could check holds up. Two of eight claims match the study. This overall rating is based only on the claims we could check. Six claims the study doesn't address.

  • 2 supported
  • 6 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

8 claims in this story

Showing all 8 claimsChoose a verdict to focus the list.

Claim 1 of 8Not coveredThe FDA approved Hibsago (bepirovirsen) for certain adults with chronic hepatitis B.View evidenceHide evidence

Why this verdict

The abstract-profile evidence describes phase 3 randomized trials in adults with noncirrhotic chronic HBV, but it does not report FDA approval or a regulatory indication for Hibsago/bepirovirsen. The population studied is relevant, but the approval claim is not verifiable from the supplied abstract-depth paper profile.

1

Study evidence

Bepirovirsen produced functional cure at week 72 in 127/650 (20%) vs 0/328 (0%) in B‑Well 1, and in 106/570 (19%) vs 0/286 (0%) in B‑Well 2.B-Well 1: 20% (127/650) vs 0% (0/328); B-Well 2: 19% (106/570) vs 0% (0/286).

“In two replicate, double-blind trials (B-Well 1 and B-Well 2), we randomly assigned adults with noncirrhotic chronic HBV infection in a 2:1 ratio to receive subcutaneous bepirovirsen (at a weekly dose of 300 mg) or placebo for 24 weeks.”
Claim 2 of 8Not coveredThe article says Hibsago is the first drug of its kind for hepatitis B and works differently from existing antiviral pills by disrupting the genetic messages the virus needs to multiply.View evidenceHide evidence

Why this verdict

The mechanism portion is broadly supported: the profile says bepirovirsen is an antisense oligonucleotide targeting HBV transcripts. However, the claim that it is the first drug of its kind for hepatitis B, and the comparison with existing antiviral pills as a regulatory/market framing, is not established in the supplied abstract-depth profile.

1

Study evidence

Bepirovirsen produced functional cure at week 72 in 127/650 (20%) vs 0/328 (0%) in B‑Well 1, and in 106/570 (19%) vs 0/286 (0%) in B‑Well 2.B-Well 1: 20% (127/650) vs 0% (0/328); B-Well 2: 19% (106/570) vs 0% (0/286).

“In two replicate, double-blind trials (B-Well 1 and B-Well 2), we randomly assigned adults with noncirrhotic chronic HBV infection in a 2:1 ratio to receive subcutaneous bepirovirsen (at a weekly dose of 300 mg) or placebo for 24 weeks.”
Claim 3 of 8Not coveredThe drug is approved for adults without cirrhosis who have been on antiviral medicine for at least six months, have suppressed virus, and have low hepatitis B surface antigen levels.View evidenceHide evidence

Why this verdict

The paper profile supports that trial participants were adults with noncirrhotic chronic HBV on stable nucleos(t)ide analogue therapy with baseline HBsAg 100–3000 IU/mL. It does not verify the stated FDA-approved indication, the 'at least six months' treatment criterion, or the full lab-eligibility wording as an approval criterion.

1

Study evidence

Bepirovirsen produced functional cure at week 72 in 127/650 (20%) vs 0/328 (0%) in B‑Well 1, and in 106/570 (19%) vs 0/286 (0%) in B‑Well 2.B-Well 1: 20% (127/650) vs 0% (0/328); B-Well 2: 19% (106/570) vs 0% (0/286).

“In two replicate, double-blind trials (B-Well 1 and B-Well 2), we randomly assigned adults with noncirrhotic chronic HBV infection in a 2:1 ratio to receive subcutaneous bepirovirsen (at a weekly dose of 300 mg) or placebo for 24 weeks.”
Claim 4 of 8Not coveredIn two clinical trials, 24% of patients given Hibsago met the requirements to stop regular medicine, while none of those given placebo did.View evidenceHide evidence

As stated24%

Why this verdict

The supplied profile reports functional cure at week 72 of 20% vs 0% in B-Well 1 and 19% vs 0% in B-Well 2. It does not report that 24% of bepirovirsen patients met requirements to stop regular medicine, nor does it describe a week-48 stopping-criteria percentage. The placebo 'none' finding matches the functional-cure endpoint, but the specific 24% stop-medicine claim is not verifiable from the abstract-depth profile.

1

Study evidence

Bepirovirsen produced functional cure at week 72 in 127/650 (20%) vs 0/328 (0%) in B‑Well 1, and in 106/570 (19%) vs 0/286 (0%) in B‑Well 2.B-Well 1: 20% (127/650) vs 0% (0/328); B-Well 2: 19% (106/570) vs 0% (0/286).

“In two replicate, double-blind trials (B-Well 1 and B-Well 2), we randomly assigned adults with noncirrhotic chronic HBV infection in a 2:1 ratio to receive subcutaneous bepirovirsen (at a weekly dose of 300 mg) or placebo for 24 weeks.”
Claim 5 of 8Not coveredThe drug carries serious risks, including severe liver reactions and low platelet counts that can lead to life-threatening bleeding, and patients need frequent blood work before and during treatment.View evidenceHide evidence

Why this verdict

The profile supports a safety signal, including more adverse events, serious adverse events, grade ≥3 events, and ALT increases with bepirovirsen. However, the abstract-depth evidence does not mention a boxed warning, low platelet counts, life-threatening bleeding, or required frequent blood work before and during treatment. Those label-level safety details are therefore not verifiable from the supplied paper profile.

1

Study evidence

Overall adverse events (pooled at 72 weeks) were more frequent with bepirovirsen than with placebo.91% (bepirovirsen) vs 73% (placebo)

“In a pooled analysis at 72 weeks, adverse events were reported in 91% of the patients in the bepirovirsen groups and in 73% of those in the placebo groups; serious adverse events were reported in 7% and 4% of the patients, respectively.”
Claim 6 of 8Not coveredThe Hepatitis B Foundation notes that there is still no complete cure for hepatitis B and advises regular follow-up with a liver specialist.View evidenceHide evidence

Why this verdict

The supplied paper profile discusses 'functional cure' as a trial endpoint, but it does not include the Hepatitis B Foundation statement, a general claim that there is no complete cure, or advice about regular follow-up with a liver specialist. This is outside what can be verified from the abstract-depth paper profile.

Claim 7 of 8SupportedPatients get Hibsago as a shot under the skin for up to six months along with their usual medicine, and after six months off the shots some who meet certain health and lab requirements may be able to stop their regular medicine.View evidenceHide evidence

As statedup to six months

Why this verdict

The profile reports subcutaneous bepirovirsen 300 mg weekly for 24 weeks, i.e. about six months, added to stable NA therapy, with eligible patients discontinuing NA therapy at week 48. The story's hedged statement that some patients meeting health/lab requirements may stop regular medicine after a period off shots is consistent with the protocol described at abstract depth.

1

Study evidence

Bepirovirsen produced functional cure at week 72 in 127/650 (20%) vs 0/328 (0%) in B‑Well 1, and in 106/570 (19%) vs 0/286 (0%) in B‑Well 2.B-Well 1: 20% (127/650) vs 0% (0/328); B-Well 2: 19% (106/570) vs 0% (0/286).

“In two replicate, double-blind trials (B-Well 1 and B-Well 2), we randomly assigned adults with noncirrhotic chronic HBV infection in a 2:1 ratio to receive subcutaneous bepirovirsen (at a weekly dose of 300 mg) or placebo for 24 weeks.”
Claim 8 of 8SupportedSix months after stopping all hepatitis B treatment, 19% of patients who got Hibsago were still keeping the virus in check and the viral protein was not detectable in their blood.View evidenceHide evidence

As stated19%

Why this verdict

The profile states that NA therapy was discontinued at week 48 and the week-72 primary endpoint was functional cure, defined as sustained HBV DNA below the lower limit of quantification and HBsAg loss. Six months after NA discontinuation, functional cure occurred in 19% in B-Well 2 and about 19% pooled across the two trials, with 20% in B-Well 1. The story's wording about keeping the virus in check and viral protein not detectable is a reasonable lay rendering of this endpoint.

1

Study evidence

Bepirovirsen produced functional cure at week 72 in 127/650 (20%) vs 0/328 (0%) in B‑Well 1, and in 106/570 (19%) vs 0/286 (0%) in B‑Well 2.B-Well 1: 20% (127/650) vs 0% (0/328); B-Well 2: 19% (106/570) vs 0% (0/286).

“In two replicate, double-blind trials (B-Well 1 and B-Well 2), we randomly assigned adults with noncirrhotic chronic HBV infection in a 2:1 ratio to receive subcutaneous bepirovirsen (at a weekly dose of 300 mg) or placebo for 24 weeks.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Abstract-depth reporting lacks confidence intervals, p-values, full safety tables, event attribution details, and subgroup analyses.

    The story does not mention these abstract-level evidentiary limitations. This matters particularly for the safety claims, where the abstract gives only selected pooled rates and limited detail on causality, timing, and management.

    From Replicate double-blind randomized placebo-controlled phase 3 trials; Pooled safety analysis of two replicate randomized

8 things the story did carry across
  • Two replicate phase 3 randomized, double-blind, placebo-controlled trials, B-Well 1 and B-Well 2, tested bepirovirsen versus placebo in chronic HBV.
  • Trial population was limited to adults with noncirrhotic chronic HBV infection on stable nucleos(t)ide analogue therapy, with baseline HBsAg 100–3000 IU/mL.
  • Intervention was subcutaneous bepirovirsen 300 mg weekly for 24 weeks, added to stable NA therapy, with NA discontinuation at week 48 for eligible patients.
  • Primary endpoint was functional cure at week 72, after NA discontinuation at week 48, defined as sustained HBV DNA below the lower limit of quantification and HBsAg loss.
  • Primary efficacy results were 20% vs 0% functional cure in B-Well 1 and 19% vs 0% in B-Well 2.
  • Safety findings included higher pooled adverse events with bepirovirsen: any adverse event 91% vs 73%, serious adverse events 7% vs 4%, grade ≥3 events during treatment 16% vs 3%, and ALT increases as the most common grade 3 event.
  • Generalizability is limited: the trials enrolled noncirrhotic adults within a specified HBsAg range on stable NA therapy, so applicability to cirrhosis or other baseline HBsAg levels is unclear from the abstract.
  • Bepirovirsen is described mechanistically as an antisense oligonucleotide targeting HBV transcripts.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

2

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoEvaluate whether fixed-duration subcutaneous bepirovirsen added to stable nucleos(t)ide analogue (NA) therapy leads to a higher rate of functional cure at week 72 (after NA discontinuation at week 48) than placebo in adults with noncirrhotic chronic HBV infection, in two replicate phase 3 randomized trials (B-Well 1 and B-Well 2).Replicate double-blind randomized placebo-controlled phase 3 trialsExpand

In plain English

Two replicate, double-blind, randomized (2:1) phase 3 trials (B-Well 1 and B-Well 2) tested fixed‑duration subcutaneous bepirovirsen 300 mg weekly for 24 weeks versus placebo in adults with noncirrhotic chronic HBV on stable nucleos(t)ide analogue (NA) therapy, with NA discontinued at week 48. The prespecified primary endpoint was functional cure at week 72 (sustained HBV DNA below the lower limit of quantification and HBsAg loss after fixed‑duration therapy). At week 72, functional cure occurred in 127 of 650 patients (20%) versus 0 of 328 (0%) in B‑Well 1, and in 106 of 570 patients (19%) versus 0 of 286 (0%) in B‑Well 2. Pooled safety reported adverse events in 91% of bepirovirsen patients versus 73% with placebo, serious adverse events in 7% versus 4%, and grade ≥3 adverse events during treatment in 16% versus 3% (alanine aminotransferase increases were the most frequent grade ≥3 event with bepirovirsen, 6%).

Key findings

  • Bepirovirsen produced functional cure at week 72 in 127/650 (20%) vs 0/328 (0%) in B‑Well 1, and in 106/570 (19%) vs 0/286 (0%) in B‑Well 2.B-Well 1: 20% (127/650) vs 0% (0/328); B-Well 2: 19% (106/570) vs 0% (0/286).
  • Safety: pooled across trials, adverse events occurred in 91% of bepirovirsen recipients vs 73% of placebo; serious adverse events in 7% vs 4%; grade ≥3 adverse events during treatment in 16% vs 3%; ALT increases were the most common grade ≥3 event with bepirovirsen (6%).Any adverse event: 91% vs 73%; serious adverse events: 7% vs 4%; grade ≥3 during treatment: 16% vs 3%; ALT grade ≥3: 6% (bepirovirsen).
“In two replicate, double-blind trials (B-Well 1 and B-Well 2), we randomly assigned adults with noncirrhotic chronic HBV infection in a 2:1 ratio to receive subcutaneous bepirovirsen (at a weekly dose of 300 mg) or placebo for 24 weeks.”
What this piece can’t prove

3 further details could not be confirmed from the summary.

2human in vivoCharacterize the safety and tolerability of bepirovirsen vs placebo during treatment and follow-up (overall AEs, serious AEs, grade ≥3 AEs, ALT elevations) in pooled and/or trial-specific analyses.Pooled safety analysis of two replicate randomized double-blind phase 3 trials (B-Well 1 and B-Well 2)Expand

In plain English

Pooled safety summary from two replicate double-blind phase 3 trials reported higher rates of adverse events, serious adverse events, and grade ≥3 adverse events with bepirovirsen than with placebo; alanine aminotransferase (ALT) increases were the most common grade 3 events with bepirovirsen.

Key findings

  • Overall adverse events (pooled at 72 weeks) were more frequent with bepirovirsen than with placebo.91% (bepirovirsen) vs 73% (placebo)
  • Serious adverse events (pooled at 72 weeks) occurred more often with bepirovirsen than with placebo.7% (bepirovirsen) vs 4% (placebo)
“In a pooled analysis at 72 weeks, adverse events were reported in 91% of the patients in the bepirovirsen groups and in 73% of those in the placebo groups; serious adverse events were reported in 7% and 4% of the patients, respectively.”
What this piece can’t prove
  • The abstract reports treatment-period grade ≥3 events and pooled 72-week safety but does not provide comprehensive longitudinal safety trajectories or management of laboratory abnormalities.

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Crossref, Europe PMC · 15 candidate papers

Candidate

Real-life Outcomes of Tenofovir Disoproxil Fumarate Monotherapy in Nucleos(t)ide Analogue-naive and Nucleos(t)ide Analogue-experienced Chronic Hepatitis B Patients: A Single-center Experience

Viral Hepatit Dergisi · 2016 · Crossref

Source (opens in a new tab)

And 9 more candidates considered.